X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Dishman Pharma with MYLAN INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs MYLAN (US) - Comparison Results

DISHMAN PHARMA    Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 DISHMAN PHARMA   MYLAN
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
MYLAN
Dec-14
DISHMAN PHARMA/
MYLAN
5-Yr Chart
Click to enlarge
High Rs3744,060-   
Low Rs1292,861-   
Sales per share (Unadj.) Rs197.81,389.9-  
Earnings per share (Unadj.) Rs21.2167.4-  
Cash flow per share (Unadj.) Rs34.7269.5-  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs179.9690.9-  
Shares outstanding (eoy) m80.69378.37-   
Bonus/Rights/Conversions -OI-  
Price / Sales ratio x1.32.5 51.1%   
Avg P/E ratio x11.920.7 57.4%  
P/CF ratio (eoy) x7.212.8 56.4%  
Price / Book Value ratio x1.45.0 27.9%  
Dividend payout %9.40-   
Avg Mkt Cap Rs m20,3061,309,348 1.6%   
No. of employees `0000.825.0 3.3%   
Total wages/salary Rs m5,3550-   
Avg. sales/employee Rs Th19,252.721,035.5 91.5%   
Avg. wages/employee Rs Th6,459.50-   
Avg. net profit/employee Rs Th2,064.12,534.1 81.5%   
INCOME DATA
Net Sales Rs m15,961525,886 3.0%  
Other income Rs m265-3,065 -8.7%   
Total revenues Rs m16,226522,821 3.1%   
Gross profit Rs m4,103130,790 3.1%  
Depreciation Rs m1,09138,624 2.8%   
Interest Rs m94422,684 4.2%   
Profit before tax Rs m2,33466,417 3.5%   
Minority Interest Rs m0-272 0.0%   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m6242,793 22.3%   
Profit after tax Rs m1,71163,352 2.7%  
Gross profit margin %25.724.9 103.4%  
Effective tax rate %26.74.2 635.5%   
Net profit margin %10.712.0 89.0%  
BALANCE SHEET DATA
Current assets Rs m11,018462,324 2.4%   
Current liabilities Rs m9,517361,445 2.6%   
Net working cap to sales %9.419.2 49.0%  
Current ratio x1.21.3 90.5%  
Inventory Days Days11078 141.5%  
Debtors Days Days35107 32.5%  
Net fixed assets Rs m16,304121,662 13.4%   
Share capital Rs m16118,597 0.9%   
"Free" reserves Rs m12,9070-   
Net worth Rs m14,516261,417 5.6%   
Long term debt Rs m4,189390,532 1.1%   
Total assets Rs m29,8051,052,965 2.8%  
Interest coverage x3.53.9 88.4%   
Debt to equity ratio x0.31.5 19.3%  
Sales to assets ratio x0.50.5 107.2%   
Return on assets %8.98.2 109.0%  
Return on equity %11.824.2 48.6%  
Return on capital %17.513.6 128.7%  
Exports to sales %24.80-   
Imports to sales %3.70-   
Net fx Rs m4,2550-   
CASH FLOW
From Operations Rs m2,78669,128 4.0%  
From Investments Rs m-1,529-54,516 2.8%  
From Financial Activity Rs m-941-18,215 5.2%  
Net Cashflow Rs m316-3,604 -8.8%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 68.12 Rs / USD

Compare DISHMAN PHARMA With: ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare DISHMAN PHARMA With: UNICHEM LAB  PLETHICO PHARMA  LUPIN LTD  SUN PHARMA  AJANTA PHARMA  



Today's Market

Sensex Ends Day in Green; Metal Stocks Top Gainers(Closing)

After opening the day in green, share markets in India witnessed positive trading activity throughout the day and ended the day on a positive note.

Related Views On News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 5-YR ANALYSIS

COMPARE DISHMAN PHARMA WITH

MARKET STATS